Analysts’ updated eps estimates for Tuesday, October 10th:

AnaptysBio (NASDAQ:ANAB) had its target price raised by Credit Suisse Group from $38.00 to $85.00.

AnaptysBio (NASDAQ:ANAB) had its price target increased by Royal Bank Of Canada from $40.00 to $79.00.

Moffett Nathanson started coverage on shares of Altice USA (NASDAQ:ATUS). The firm issued a neutral rating on the stock.

Wells Fargo & Company started coverage on shares of Capital One Financial Corporation (NYSE:COF). The firm issued an outperform rating on the stock.

DCT Industrial Trust (NYSE:DCT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $66.00 price target on the stock. According to Zacks, “DCT INDUSTRIAL is a leading industrial real estate company that owns, operates and develops high quality bulk distribution and light industrial properties in high volume distribution markets in the U.S. and Mexico. “

Wells Fargo & Company began coverage on shares of Discover Financial Services (NYSE:DFS). They issued a market perform rating on the stock.

Diplomat Pharmacy (NYSE:DPLO) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. Zacks Investment Research currently has $24.00 price target on the stock. According to Zacks, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan. “

Diana Shipping inc. (NYSE:DSX) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Diana Shipping Inc. is a global provider of shipping transportation services. They specialize in transporting dry bulk cargoes, including such commodities as iron ore, coal, grain and other materials along worldwide shipping routes. “

Ecopetrol (NYSE:EC) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $11.00 price target on the stock. According to Zacks, “ECOPETROL S.A. is a Colombia-based petroleum company. The Company is focused on identifying opportunities primarily within the eastern Llanos Basin of Colombia, as well as in other areas in Colombia and northern Peru. The Company’s operation includes the extraction, collection, treatment, storage and pumping or compression of hydrocarbons. Ecopetrol has four management divisions to handle the operation of 163 production fields. Ecopetrol’s production is concentrated in the upper, middle and lower Magdalena, the Eastern Plans and the Caribbean, and the provinces of Putumayo, Cesar and Norte de Santander. “

Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

Envestnet (NYSE:ENV) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $61.00 price target on the stock. According to Zacks, “Envestnet, Inc. is an independent provider of technology-enabled, Web-based investment solutions and services to financial advisors. The Company’s technology platform allows financial advisors to provide their clients with a wide range of investment solutions and services. It offers risk assessment and selection of investment strategies, asset allocation models, research and due diligence, portfolio construction, proposal generation and paperwork preparation, model management and account rebalancing, account monitoring, customized fee billing, overlay services covering asset allocation, tax management and socially responsible investing, aggregated multi-custodian performance reporting and communication tools, as well as access to a range of third-party asset custodians. Envestnet focuses its technology development efforts and its sales and marketing approach on addressing financial advisors’ front, middle and back office needs. Envestnet, Inc. is headquartered in Chicago, Illinois. “

Eldorado Resorts (NASDAQ:ERI) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Eldorado Resorts, Inc. is a casino entertainment company. It provides casino and entertainment services primarily in Nevada and Louisiana, United States. The Company’s facilities and services include casino games; hotels; entertainment and events; signature and casual restaurants; various venues; and guest services. Its casino also provides facilities for meetings and special events; catering and banquet services; and golf, ski, Reno bowling, baseball, basecamp climbing, truckee river, Reno fernley raceway, and museum services. Eldorado Resorts, Inc. is based in Reno, Nevada. “

Second Sight Medical Products (NASDAQ:EYES) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Second Sight Medical Products, Inc. is a medical device company. It develops, manufactures, and markets implantable prosthetic devices to restore some functional vision to blind patients. The Company provides Argus II system, an implantable neurostimulation device for the treatment of outer retinal degenerations, such as retinitis pigmentosa. Second Sight Medical Products, Inc. is headquartered in Sylmar, California. “

Fibrocell Science (NASDAQ:FCSC) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “

KeyCorp started coverage on shares of FedEx Corporation (NYSE:FDX). KeyCorp issued an overweight rating on the stock.

Harley-Davidson (NYSE:HOG) had its buy rating reissued by analysts at Stifel Nicolaus. Stifel Nicolaus currently has a $48.00 price target on the stock, down from their previous price target of $51.00.

Intel Corporation (NASDAQ:INTC) had its price target boosted by Susquehanna Bancshares Inc from $45.00 to $46.00. Susquehanna Bancshares Inc currently has a positive rating on the stock.

Deutsche Bank AG began coverage on shares of POWERSHARES GLBAL FUNDS IRELAND PLC POWERSHARES EQQQ NASDAQ-100 UCITS ETF (NASDAQ:IRELAND). Deutsche Bank AG issued a buy rating and a $6.00 target price on the stock.

K2M Group Holdings (NASDAQ:KTWO) had its outperform rating reaffirmed by analysts at JMP Securities. They currently have a $25.00 price target on the stock, down from their previous price target of $30.00.

lululemon athletica inc. (NASDAQ:LULU) had its outperform rating reiterated by analysts at Oppenheimer Holdings, Inc.. They currently have a $68.00 price target on the stock.

SunTrust Banks, Inc. assumed coverage on shares of National Health Investors (NYSE:NHI). They issued a hold rating on the stock.

Fearnley Fonds assumed coverage on shares of Pangaea Logistics Solutions (NASDAQ:PANL). Fearnley Fonds issued a buy rating and a $3.60 target price on the stock.

SodaStream International (NASDAQ:SODA) had its positive rating reissued by analysts at Susquehanna Bancshares Inc. They currently have a $90.00 target price on the stock, up from their previous target price of $88.00.

Wells Fargo & Company began coverage on shares of Synchrony Financial (NYSE:SYF). The firm issued a market perform rating on the stock.

Credit Suisse Group initiated coverage on shares of Tuniu Corporation (NASDAQ:TOUR). They issued an outperform rating on the stock.

T. Rowe Price Group (NASDAQ:TROW) had its buy rating reaffirmed by analysts at Jefferies Group LLC. Jefferies Group LLC currently has a $104.00 target price on the stock, up from their previous target price of $96.00.

Deutsche Bank AG assumed coverage on shares of Recon Capital Series Trust Recon Capital FTSE 100 ETF (NYSE:UK). The firm issued a hold rating and a $4.00 price target on the stock.

Receive News & Ratings for AnaptysBio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc and related companies with MarketBeat.com's FREE daily email newsletter.